In this series, “Promise or Peril: Alarming COVID-19 mRNA Vaccine Issues,” we explore how the introduction of mRNA technology lacked an adequate regulatory framework, setting the stage for serious adverse events and other concerns related to inadequate safety testing of lipid nanoparticles, spike protein, and residual DNA and lipid-related impurities as well as truncated/modified mRNA species.
Previously: In Part 1 of this series, FDA Overhaul Needed for New Vaccines and mRNA Therapies, we introduced how the FDA relaxed the rules for mRNA vaccines compared to mRNA therapies. We also discussed the available data regarding lipid nanoparticle (LNP) distribution throughout the body based on animal testing, the fact that human testing was not done, and the lack of mRNA or spike protein biodistribution data for the COVID-19 mRNA vaccine. We now turn to the health implications of these compounds in the body….